Selected research
Industry Research
Direct Oral Anticoagulants (DOACs) Industry Research Report 2026
Market perspective
The global Direct Oral Anticoagulants (DOACs) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Direct Oral Anticoagulants (DOACs) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Direct Oral Anticoagulants (DOACs) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Direct Oral Anticoagulants (DOACs) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Direct Oral Anticoagulants (DOACs) include Accord Healthcare, Apotex, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Janssen Pharmaceuticals, Teva Pharmaceutical and Viatris, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Direct Oral Anticoagulants (DOACs) market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Direct Oral Anticoagulants (DOACs) Market by Company
Accord Healthcare
Apotex
Boehringer Ingelheim
Bristol Myers Squibb
Daiichi Sankyo
GlaxoSmithKline
Janssen Pharmaceuticals
Teva Pharmaceutical
Viatris
Bayer
Pfizer
Mylan
Sandoz
Direct Oral Anticoagulants (DOACs) Segment by Type
Oral Factor Xa Inhibitors
Direct Thrombin Inhibitors (DTIs)
Direct Oral Anticoagulants (DOACs) Segment by Application
Pulmonary Embolism
Deep Vein Thrombosis
Atrial Fibrillation
Other
Direct Oral Anticoagulants (DOACs) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Direct Oral Anticoagulants (DOACs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Direct Oral Anticoagulants (DOACs) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Direct Oral Anticoagulants (DOACs).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Direct Oral Anticoagulants (DOACs) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Direct Oral Anticoagulants (DOACs) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Direct Oral Anticoagulants (DOACs) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral Factor Xa Inhibitors
- Direct Thrombin Inhibitors (DTIs)
Applications
- Pulmonary Embolism
- Deep Vein Thrombosis
- Atrial Fibrillation
- Other
Companies covered
- Accord Healthcare
- Apotex
- Boehringer Ingelheim
- Bristol Myers Squibb
- Daiichi Sankyo
- GlaxoSmithKline
- Janssen Pharmaceuticals
- Teva Pharmaceutical
- Viatris
- Bayer
- Pfizer
- Mylan
- Sandoz
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Direct Oral Anticoagulants (DOACs) Market Size (2021-2032)
- 2.2.2 Global Direct Oral Anticoagulants (DOACs) Sales (2021-2032)
- 2.2.3 Global Direct Oral Anticoagulants (DOACs) Market Average Price (2021-2032)
- 2.3 Direct Oral Anticoagulants (DOACs) by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oral Factor Xa Inhibitors
- 2.3.3 Direct Thrombin Inhibitors (DTIs)
- 2.4 Direct Oral Anticoagulants (DOACs) by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Pulmonary Embolism
- 2.4.3 Deep Vein Thrombosis
- 2.4.4 Atrial Fibrillation
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Direct Oral Anticoagulants (DOACs) Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Direct Oral Anticoagulants (DOACs) Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Direct Oral Anticoagulants (DOACs) Revenue of Manufacturers (2021-2026)
- 3.4 Global Direct Oral Anticoagulants (DOACs) Average Price by Manufacturers (2021-2026)
- 3.5 Global Direct Oral Anticoagulants (DOACs) Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Direct Oral Anticoagulants (DOACs), Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Direct Oral Anticoagulants (DOACs), Product Type & Application
- 3.8 Global Manufacturers of Direct Oral Anticoagulants (DOACs), Established Date
- 3.9 Global Direct Oral Anticoagulants (DOACs) Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Accord Healthcare
- 4.1.1 Accord Healthcare Company Information
- 4.1.2 Accord Healthcare Business Overview
- 4.1.3 Accord Healthcare Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Accord Healthcare Direct Oral Anticoagulants (DOACs) Product Portfolio
- 4.1.5 Accord Healthcare Recent Developments
- 4.2 Apotex
- 4.2.1 Apotex Company Information
- 4.2.2 Apotex Business Overview
- 4.2.3 Apotex Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Apotex Direct Oral Anticoagulants (DOACs) Product Portfolio
- 4.2.5 Apotex Recent Developments
- 4.3 Boehringer Ingelheim
- 4.3.1 Boehringer Ingelheim Company Information
- 4.3.2 Boehringer Ingelheim Business Overview
- 4.3.3 Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Product Portfolio
- 4.3.5 Boehringer Ingelheim Recent Developments
- 4.4 Bristol Myers Squibb
- 4.4.1 Bristol Myers Squibb Company Information
- 4.4.2 Bristol Myers Squibb Business Overview
- 4.4.3 Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Product Portfolio
- 4.4.5 Bristol Myers Squibb Recent Developments
- 4.5 Daiichi Sankyo
- 4.5.1 Daiichi Sankyo Company Information
- 4.5.2 Daiichi Sankyo Business Overview
- 4.5.3 Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Product Portfolio
- 4.5.5 Daiichi Sankyo Recent Developments
- 4.6 GlaxoSmithKline
- 4.6.1 GlaxoSmithKline Company Information
- 4.6.2 GlaxoSmithKline Business Overview
- 4.6.3 GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Product Portfolio
- 4.6.5 GlaxoSmithKline Recent Developments
- 4.7 Janssen Pharmaceuticals
- 4.7.1 Janssen Pharmaceuticals Company Information
- 4.7.2 Janssen Pharmaceuticals Business Overview
- 4.7.3 Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Product Portfolio
- 4.7.5 Janssen Pharmaceuticals Recent Developments
- 4.8 Teva Pharmaceutical
- 4.8.1 Teva Pharmaceutical Company Information
- 4.8.2 Teva Pharmaceutical Business Overview
- 4.8.3 Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Product Portfolio
- 4.8.5 Teva Pharmaceutical Recent Developments
- 4.9 Viatris
- 4.9.1 Viatris Company Information
- 4.9.2 Viatris Business Overview
- 4.9.3 Viatris Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Viatris Direct Oral Anticoagulants (DOACs) Product Portfolio
- 4.9.5 Viatris Recent Developments
- 4.10 Bayer
- 4.10.1 Bayer Company Information
- 4.10.2 Bayer Business Overview
- 4.10.3 Bayer Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Bayer Direct Oral Anticoagulants (DOACs) Product Portfolio
- 4.10.5 Bayer Recent Developments
- 4.11 Pfizer
- 4.11.1 Pfizer Company Information
- 4.11.2 Pfizer Business Overview
- 4.11.3 Pfizer Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Pfizer Direct Oral Anticoagulants (DOACs) Product Portfolio
- 4.11.5 Pfizer Recent Developments
- 4.12 Mylan
- 4.12.1 Mylan Company Information
- 4.12.2 Mylan Business Overview
- 4.12.3 Mylan Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Mylan Direct Oral Anticoagulants (DOACs) Product Portfolio
- 4.12.5 Mylan Recent Developments
- 4.13 Sandoz
- 4.13.1 Sandoz Company Information
- 4.13.2 Sandoz Business Overview
- 4.13.3 Sandoz Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Sandoz Direct Oral Anticoagulants (DOACs) Product Portfolio
- 4.13.5 Sandoz Recent Developments
5 Global Direct Oral Anticoagulants (DOACs) Market Scenario by Region
- 5.1 Global Direct Oral Anticoagulants (DOACs) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Direct Oral Anticoagulants (DOACs) Sales by Region: 2021-2032
- 5.2.1 Global Direct Oral Anticoagulants (DOACs) Sales by Region: 2021-2026
- 5.2.2 Global Direct Oral Anticoagulants (DOACs) Sales by Region: 2027-2032
- 5.3 Global Direct Oral Anticoagulants (DOACs) Revenue by Region: 2021-2032
- 5.3.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Region: 2021-2026
- 5.3.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Region: 2027-2032
- 5.4 North America Direct Oral Anticoagulants (DOACs) Market Facts & Figures by Country
- 5.4.1 North America Direct Oral Anticoagulants (DOACs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2032)
- 5.4.3 North America Direct Oral Anticoagulants (DOACs) Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Direct Oral Anticoagulants (DOACs) Market Facts & Figures by Country
- 5.5.1 Europe Direct Oral Anticoagulants (DOACs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2032)
- 5.5.3 Europe Direct Oral Anticoagulants (DOACs) Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Direct Oral Anticoagulants (DOACs) Market Facts & Figures by Country
- 5.6.1 Asia Pacific Direct Oral Anticoagulants (DOACs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Direct Oral Anticoagulants (DOACs) Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Direct Oral Anticoagulants (DOACs) Market Facts & Figures by Country
- 5.7.1 South America Direct Oral Anticoagulants (DOACs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2032)
- 5.7.3 South America Direct Oral Anticoagulants (DOACs) Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Direct Oral Anticoagulants (DOACs) Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Direct Oral Anticoagulants (DOACs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Direct Oral Anticoagulants (DOACs) Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2032)
- 6.1.1 Global Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2021-2032)
- 6.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Type (2021-2032)
- 6.2.1 Global Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Type (2021-2032)
- 6.3 Global Direct Oral Anticoagulants (DOACs) Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2032)
- 7.1.1 Global Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Application (2021-2032)
- 7.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Application (2021-2032)
- 7.2.1 Global Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Application (2021-2032)
- 7.3 Global Direct Oral Anticoagulants (DOACs) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Direct Oral Anticoagulants (DOACs) Value Chain Analysis
- 8.1.1 Direct Oral Anticoagulants (DOACs) Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Direct Oral Anticoagulants (DOACs) Production Mode & Process
- 8.2 Direct Oral Anticoagulants (DOACs) Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Direct Oral Anticoagulants (DOACs) Distributors
- 8.2.3 Direct Oral Anticoagulants (DOACs) Customers
9 Global Direct Oral Anticoagulants (DOACs) Analyzing Market Dynamics
- 9.1 Direct Oral Anticoagulants (DOACs) Industry Trends
- 9.2 Direct Oral Anticoagulants (DOACs) Industry Drivers
- 9.3 Direct Oral Anticoagulants (DOACs) Industry Opportunities and Challenges
- 9.4 Direct Oral Anticoagulants (DOACs) Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst